Skip to main content

Advertisement

SpringerLink
Log in

Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

In spite of the good prognosis of patients with early-stage melanoma, there is a substantial proportion of them that develop local or distant relapses. With the introduction of targeted and immune therapies for advanced melanoma, including at the adjuvant setting, early detection of recurrent melanoma and/or second primary lesions is crucial to improve clinical outcomes. However, there is a lack of universal guidelines regarding both frequency of surveillance visits and diagnostic imaging and/or laboratory evaluations. In this article, a multidisciplinary expert panel recommends, after careful review of relevant data in the field, a consensus- and experience-based follow-up strategy for melanoma patients, taking into account prognostic factors and biomarkers and the high-risk periods and patterns of recurrence in each (sub) stage of the disease. Apart from the surveillance intensity, healthcare professionals should focus on patients’ education to perform regular self-examinations of the skin and palpation of lymph nodes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392:971–84.

    Article  PubMed  Google Scholar 

  2. Pasquali S, Hadjinicolaou AV, ChiarionSileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane database Syst Rev. 2018;2:CD011123–CD011123.

    PubMed  Google Scholar 

  3. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1.

    Article  PubMed  CAS  Google Scholar 

  4. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801.

    Article  CAS  PubMed  Google Scholar 

  6. Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.

    Article  CAS  PubMed  Google Scholar 

  7. Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.

    Article  CAS  PubMed  Google Scholar 

  9. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–23.

    Article  CAS  PubMed  Google Scholar 

  10. Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland. Australia J Invest Dermatol. 2015;135:1190–3.

    Article  CAS  PubMed  Google Scholar 

  11. Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol. 2017;76:258–63.

    Article  PubMed  Google Scholar 

  12. Thomas DC, Han G, Leong SP, Kashani-Sabet M, Vetto J, Pockaj B, et al. Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival. Ann Surg Oncol. 2019;26:2254–62.

    Article  PubMed  Google Scholar 

  13. Leiter U, Buettner PG, Eigentler TK, Bröcker EB, Voit C, Gollnick H, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German central malignant melanoma registry. J Am Acad Dermatol. 2012;66:37–45.

    Article  PubMed  Google Scholar 

  14. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global review of melanoma follow-up guidelines. J Clin Aesthet Dermato. 2013;6:18–26.

    Google Scholar 

  15. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidencebased changes in the American Joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, et al. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. J Dermatol Sci. 2019;94:284–9.

    Article  PubMed  Google Scholar 

  17. Kanaki T, Stang A, Gutzmer R, Zimmer L, Chorti E, Sucker A, et al. Impact of American joint committee on cancer 8th edition classification on staging and survival of patients with melanoma. Eur J Cancer. 2019;119:18–29.

    Article  PubMed  Google Scholar 

  18. Bajaj S, Donnelly D, Call M, Johannet P, Moran U, Polsky D, et al. Melanoma prognosis: accuracy of the American joint Committee on cancer staging manual eighth edition. J Natl Cancer Inst. 2020;112:921–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32:2479–85.

    Article  PubMed  Google Scholar 

  20. Han D, Han G, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, et al. Factors predicting survival in thick melanoma: do all thick melanomas have the same prognosis? Surgery. 2020;168:518–26.

    Article  PubMed  Google Scholar 

  21. Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208–50.

    Article  PubMed  Google Scholar 

  22. Tejera-Vaquerizo A, Fernández-Figueras MT, Santos-Briz Á, Ríos-Martín JJ, Monteagudo C, Fernández-Flores Á, et al. Protocol for the histologic diagnosis of cutaneous melanoma: consensus statement of the Spanish society of pathology and the Spanish academy of dermatology and venereology (AEDV) for the national cutaneous melanoma registry. Actas DermoSifiliogr. 2021;112:32–43.

    Article  CAS  PubMed  Google Scholar 

  23. Ny L, Hernberg M, Nyakas M, Koivunen J, Oddershede L, Yoon M, et al. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. Acta Oncol. 2020;59:833–44.

    Article  CAS  PubMed  Google Scholar 

  24. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American joint committee on cancer individualized melanoma patient outcome prediction tool with a 31-gene expression profile-based classification. J Am Acad Dermatol. 2017;76:818-825.e3.

    Article  PubMed  Google Scholar 

  26. Hsueh EC, DeBloom JR, Lee J, Sussman JJ, Covington KR, Middlebrook B, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol. 2017;10:152.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80:149-157.e4.

    Article  CAS  PubMed  Google Scholar 

  28. Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1479 patients. J Am Acad Dermatol. 2020;83:745–53.

    Article  PubMed  Google Scholar 

  29. Botella-Estrada R, Boada-García A, Carrera-Álvarez C, Fernández-Figueras M, González-Cao M, Moreno-Ramírez D, et al. Clinical practice guideline on melanoma from the Spanish academy of dermatology and venereology (AEDV). Actas Dermosifiliog. 2021;112:142–52.

    Article  CAS  Google Scholar 

  30. Fonseca IB, Lindote MVN, Monteiro MR, Doria Filho E, Pinto CAL, Jafelicci AS, et al. Sentinel node status is the most important prognostic information for clinical stage IIB and IIC melanoma patients. Ann Surg Oncol. 2020;27:4133–40.

    Article  PubMed  Google Scholar 

  31. Crystal J, Thompson JF, Cochran AJ, Hyngstrom J, Caraco C, Zager JS, et al. Sentinel lymph node biopsy in melanoma is therapeutic: predictors of long-term node basin control with SLN biopsy alone. Ann Surg Oncol. 2020;27:S31–2.

    Google Scholar 

  32. Pizarro Á. Sentinel lymph node biopsy in melanoma does have therapeutic utility. Actas DermoSifiliogr. 2020;111:536–7.

    Article  CAS  PubMed  Google Scholar 

  33. Ipenburg NA, Thompson JF, Uren RF, Chung D, Nieweg OE. Focused ultrasound surveillance of lymph nodes following lymphoscintigraphy without sentinel node biopsy: a useful and safe strategy in elderly or frail melanoma patients. Ann Surg Oncol. 2019;26:2855–63.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37:3000–8.

    Article  CAS  PubMed  Google Scholar 

  36. Damude S, Wevers KP, Murali R, Kruijff S, Hoekstra HJ, Bastiaannet E. A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma. Eur J Surg Oncol. 2017;43:1753–9.

    Article  CAS  PubMed  Google Scholar 

  37. Rossi CR, Mocellin S, Campana LG, Borgognoni L, Sestini S, Giudice G, et al. Prediction of non-sentinel node status in patients with melanoma and positive sentinel node biopsy: an Italian melanoma intergroup (IMI) study. Ann Surg Oncol. 2018;25:271–9.

    Article  PubMed  Google Scholar 

  38. Bellomo D, Arias-Mejias SM, Ramana C, Heim JB, Quattrocchi E, Sominidi-Damodaran S, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020;4:319–34.

    Article  PubMed  Google Scholar 

  39. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Melanoma: Cutaneous, Version 2.2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed 14 Feb 2022

  40. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1884–901.

    Article  CAS  PubMed  Google Scholar 

  41. Tas F, Erturk K. Relapse patterns in patients with local and regional cutaneous melanoma. Clin Transl Oncol. 2019;21:412–9.

    Article  CAS  PubMed  Google Scholar 

  42. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, et al. Cumulative incidence and predictors of CNS metastasis for patients with american joint committee on cancer 8th edition stage III melanoma. J Clin Oncol. 2020;38:1429–41.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24:939–46.

    Article  PubMed  Google Scholar 

  44. Robinson JK, Reavy R, Mallett KA, Turrisi R. Remote skin self-examination training of melanoma survivors and their skin check partners: a randomized trial and comparison with in-person training. Cancer Med. 2020;9:7301–9.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res. 2010;20(3):240–6.

    Article  PubMed  Google Scholar 

  46. Lim KHJ, Spain L, Barker C, Georgiou A, Walls G, Gore M, et al. Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. ESMO open. 2018;3:e000317.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu W-J, Wolchok JD, Joshua AM, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 2018;24:4960–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. National Institute for Health and Care Excellence (NICE). Melanoma: assessment and management (NG14). 2015. https://www.nice.org.uk/guidance/ng14/resources/melanoma-assessment-and-management-pdf-1837271430853. Accessed 12 Mar 2021

  49. Podlipnik S, Carrera C, Sánchez M, Arguis P, Olondo ML, Vilana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American joint committee on cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75:516–24.

    Article  PubMed  Google Scholar 

  50. Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, et al. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017;27:335–41.

    Article  PubMed  Google Scholar 

  51. Stahlie EHA, van der Hiel B, Stokkel MPM, Schrage YM, van Houdt WJ, Wouters MW, et al. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma. J Surg Oncol. 2020;122:1328–36.

    Article  PubMed  Google Scholar 

  52. Ibrahim AM, Le May M, Bossé D, Marginean H, Song X, Nessim C, et al. Imaging intensity and survival outcomes in high-risk resected melanoma treated by systemic therapy at recurrence. Ann Surg Oncol. 2020;27:3683–91.

    Article  PubMed  Google Scholar 

  53. Kurtz J, Beasley GM, Agnese D, Kendra K, Olencki TE, Terando A, et al. Surveillance strategies in the follow-up of melanoma patients: too much or not enough? J Surg Res. 2017;214:32–7.

    Article  PubMed  Google Scholar 

  54. Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA, et al. Recurrence patterns in patients with stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol. 2020;122:1770–7.

    Article  PubMed  Google Scholar 

  55. Park TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24:947–51.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Freeman M, Laks S. Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship. Melanoma Manag. 2019;6:MMT2.

    Article  Google Scholar 

  57. Ozdemir S, McCook B, Klassen C. Whole-body versus routine skull base to mid-thigh (18)F-Fluorodeoxyglucose positron emission tomography/computed tomography in patients with malignant melanoma. J Clin Imaging Sci. 2020;10:47.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma.” J Ger Soc Dermatology. 2013;11(Suppl 6):1–116 (1-126).

    Google Scholar 

  59. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. part 1: diagnostics - update 2019. Eur J Cancer. 2020;126:141–58.

    Article  CAS  PubMed  Google Scholar 

  60. Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K, et al. Patient symptoms are the most frequent indicators of recurrence in patients with american joint committee on Cancer stage II melanoma. J Am Coll Surg. 2017;224:652–9.

    Article  PubMed  Google Scholar 

  61. Podlipnik S, Moreno-Ramírez D, Carrera C, Barreiro A, Manubens E, Ferrandiz-Pulido L, et al. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American joint committee on cancer stage IIB, IIC and III malignant melanoma. Br J Dermatol. 2019;180:1190–7.

    Article  CAS  PubMed  Google Scholar 

  62. Petrelli F, Ardito R, Merelli B, Lonati V, Cabiddu M, Seghezzi S, et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Res. 2019;29:1–12.

    Article  CAS  PubMed  Google Scholar 

  63. Ertekin SS, Podlipnik S, Ribero S, Molina R, Rios J, Carrera C, et al. Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2020;34:1482–8.

    Article  CAS  PubMed  Google Scholar 

  64. Kang S, Ahn B-C, Hong CM, Song B-I, Lee HJ, Jeong SY, et al. Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma? Nuklearmedizin. 2011;50:116–21.

    Article  CAS  PubMed  Google Scholar 

  65. Son SH, Kang SM, Jeong SY, Lee S-W, Lee S-J, Lee J, et al. Prognostic value of volumetric parameters measured by pretreatment 18F FDG PET/CT in patients with cutaneous malignant melanoma. Clin Nucl Med. 2016;41:e266–73.

    Article  PubMed  Google Scholar 

  66. Malik D, Sood A, Mittal BR, Basher RK, Bhattacharya A, Singh G. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery. World J Nucl Med. 2019;18:176–82.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol. 2018;29:1569–74.

    Article  CAS  PubMed  Google Scholar 

  68. Reinert CP, Gatidis S, Sekler J, Dittmann H, Pfannenberg C, la Fougère C, et al. Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing (18)F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. Cancer Imaging. 2020;20:44.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Huang SK, Hoon DSB. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol. 2016;10:450–63.

    Article  PubMed  CAS  Google Scholar 

  70. Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. Ann Oncol. 2018;29:490–6.

    Article  CAS  PubMed  Google Scholar 

  71. Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, et al. Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res. 2018;31:73–81.

    Article  CAS  PubMed  Google Scholar 

  72. Váraljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A, et al. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precis Oncol. 2020;3:1–12.

    Google Scholar 

  73. Mujumdar UJ, Hay JL, Monroe-Hinds YC, Hummer AJ, Begg CB, Wilcox HB, et al. Sun protection and skin self-examination in melanoma survivors. Psychooncology. 2009;18:1106–15.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Menzies S, Barry R, Ormond P. Multiple primary melanoma: a single centre retrospective review. Melanoma Res. 2017;27:638–40.

    Article  PubMed  Google Scholar 

  75. Beroukhim K, Pourang A, Eisen DB. Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol. 2020;82:683–9.

    Article  CAS  PubMed  Google Scholar 

  76. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159:669–76.

    CAS  PubMed  Google Scholar 

  77. Salerni G, Terán T, Puig S, Malvehy J, Zalaudek I, Argenziano G, et al. Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the international dermoscopy Society. J Eur Acad Dermatol Venereol. 2013;27:805–14.

    Article  CAS  PubMed  Google Scholar 

  78. Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, et al. Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane database Syst Rev. 2018;12:CD011902–CD011902.

    PubMed  Google Scholar 

  79. Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol. 2012;132:1763–74.

    Article  CAS  PubMed  Google Scholar 

  80. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:677.e1-677.e14.

    Article  Google Scholar 

  81. Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, et al. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015;3:210.

    PubMed  PubMed Central  Google Scholar 

  82. Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017;36:77–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Klapperich ME, Bowen GM, Grossman D. Current controversies in early-stage melanoma: questions on management and surveillance. J Am Acad Dermatol. 2019;80:15–25.

    Article  PubMed  Google Scholar 

  84. Vale L, Kunonga P, Coughlan D, Kontogiannis V, Astin M, Beyer F, et al. Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. Health Technol Assess. 2021;25:1–178.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Anabel Herrero PhD who provided medical writing support on behalf of Springer Healthcare, with funding from Novartis Pharmaceuticals.

Funding

Novartis Pharmaceuticals provided economic funding for this work. The sponsor had no role in the design, the analysis and the interpretation of the data, the wording of the article or the decision to send the article for publication.

Author information

Authors and Affiliations

  1. Medical Oncology Department, Hospital Universitario Lucus Augusti de Lugo, C/Ulises Romero nº1. 27003, Lugo, Spain

    Begoña Campos-Balea

  2. Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain

    Ovidio Fernández-Calvo

  3. Servicio de Radiodiagnóstico, Imagen Oncológica, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain

    Roberto García-Figueiras

  4. Servicio de Anatomía Patológica, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain

    Carlos Neira

  5. Dermatology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

    Carmen Peña-Penabad

  6. Medical Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain

    Carmela Rodríguez-López

  7. Medical Oncology Department, Hospital Arquitecto Marcide de Ferrol, A Coruña, Spain

    Rocío Vílchez-Simo

  8. Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

    María Quindós-Varela

Authors
  1. Begoña Campos-Balea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ovidio Fernández-Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto García-Figueiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos Neira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carmen Peña-Penabad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carmela Rodríguez-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rocío Vílchez-Simo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. María Quindós-Varela
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to this manuscript. The manuscript has been read and approved for submission by all the named authors.

Corresponding author

Correspondence to Begoña Campos-Balea.

Ethics declarations

Conflict of interest

Begoña Campos Balea has received honoraria as consultant or advisory boards from Roche, Sanofi, and Boehringer. She has received speaking honoraria from Roche, Pierre-Fabre, Novartis, Bristol-Myers-Squibb, Astra-Zeneca, MSD, and Sanofi. Ovidio Fernández-Calvo has received honoraria as consultant or advisory boards from Astellas Pharma, Roche, Pfizer, Bristol-Myers-Squibb, Sanofi, EUSA Pharma and Sanofi. He has received speaking honoraria from Pierre-Fabre, Novartis, Bristol-Myers-Squibb, Ipsen, Roche, Astellas Pharma, Bayer, and Janssen. Roberto García-Figueiras and Carlos Neira declares no conflicts of interest. Carmen Peña Penabad has received speaking honoraria from Roche, Novartis, Bristol-Myers-Squibb, Sanofi and LeoPharma. Carmela Rodríguez-López has received honoraria as consultant or advisory boards from Novartis. She has received speaking honoraria from Pierre-Fabre, Novartis, Bristol-Myers-Squibb, Roche, MSD, and Ipsen. Rocio Vilchez Simo has received honoraria as consultant or advisory boards from Novartis. She has received speaking honoraria from Novartis, Sanofi, Eisai, Roche and Pfyzer. María Quindós-Varela reports honoraria and advisory/consultancy from AstraZeneca, GSK, MerckSharp and Dohme, Novartis, PharmaMar, Roche, Bristol-Myers-Squibb, and Pierre Fabre. She has received Travel/Accommodation/Expenses from AstraZeneca, Pharmamar, Roche, GSK, Novartis Merck Sharp and Dohme and speakers bureau from AstraZeneca, GSK, MerckSharp and Dohme, Novartis, PharmaMar, Roche, Bristol-Myers-Squibb, and Pierre-Fabre.

Ethical approval

This article does not contain any studies with human or animal participants performed by any of the authors. So, ethical approval and informed consent are not necessary.

Informed consent

This article does not contain studies with human or animal participants, So the Informed consent statement is not necessary.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campos-Balea, B., Fernández-Calvo, O., García-Figueiras, R. et al. Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus. Clin Transl Oncol 24, 1515–1523 (2022). https://doi.org/10.1007/s12094-022-02822-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-02822-x

Keywords

Search

Navigation